The combined use of PD‐L1 and CTLA‐4 dual‐ICIs therapy with concurrent CRT has shown promising results, significantly improving OS and PFS in locally advanced ESCC patients [105, 106]. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.